KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials.

Marcelo Antonini, André Mattar, Marcelo Madeira, Francisco Pimentel Cavalcante, Felipe Pereira Zerwes, Fabricio Palermo Brenelli, Antonio Luis Frasson, Eduardo Camargo Millen, Giuliano Tavares Tosello, Marina Diogenes Teixeira, Gil Facina, Sabrina Monteiro Rondelo, Renata Arakelian, Larissa Chrispim de Oliveira, Lucas M Okumura, Patrícia Carvalho Baruel, Henrique Lima Couto, Marina Fleury de Figueiredo, Rogerio Fenile, Renata Montarroyos Leite, Pedro Paulo de Andrade Gomes, Gabriela de Oliveira Gomes, Leonardo Ribeiro Soares, Ruffo Freitas-Jr, Luiz Henrique Gebrim

Clin Breast Cancer 26(6) 161-178.e1

PMID42161782
PMCID-
DOI10.1016/j.clbc.2026.04.016
发表日期2026-05-20
摘要

摘要

Neoadjuvant therapy (NAT) is standard treatment for triple-negative breast cancer (TNBC) but toxicity is a major concern. This study aimed to assess the incidence and risk of grade ≥ 3 adverse events (AEs) associated with NAT in nonmetastatic TNBC. We performed a systematic review and meta-analysis registered in PROSPERO (CRD42024562785). Four databases were searched for randomized controlled trials (RCTs) from 2010 to 2025 reporting grade ≥ 3 AEs in TNBC. Pooled prevalence and risk ratios (RRs) were estimated using random-effects models. Six RCTs including 3316 patients were analyzed. Neutropenia was the most common severe AE, with pooled prevalence of 33.5% for ICIs, 23.7% for PARP inhibitors, and 16.0% for platinum regimens. PARP inhibitors significantly increased neutropenia (RR 1.84) and anemia (RR 2.08), while thrombocytopenia risk was also higher (RR 3.56). ICIs were associated with more febrile neutropenia (14.9%) but without a significant risk increase. ALT elevation was more frequent with platinum regimens (6.4%). Fatal AEs were rare (<1%). NAT improves outcomes in TNBC but is associated with substantial severe toxicity. PARP inhibitors carry the greatest hematologic risks, ICIs add immune-related AEs, and platinum regimens showed the lowest AE burden. Biomarker-driven patient selection and vigilant monitoring are essential to optimize safety.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。